Savill P. Spironolactone in heart failure with preserved ejection fraction. Practitioner 2014; 258 (1774):10

Spironolactone in heart failure with preserved ejection fraction

23 Sep 2014Pais-up subscribers

Spironolactone did not significantly reduce deaths in patients with heart failure and preserved ejection fraction, however it did cut hospitalisations for heart failure, the TOPCAT study has shown. This was an international, multicentre, randomised, double-blind trial of patients with symptomatic heart failure and left ventricular ejection fraction ≥ 45%. A total of 3,445 patients were randomised to receive either spironolactone (15 to 45 mg daily) or placebo. The mean age of patients was 68.7 in both groups.

Paid-up subscribersThis article can be accessed only if you are a paid-up subscriber to The Practitioner.

To view current online and print subscription rates, and to contact the subscription department, click Subscribe today .

To buy this article (£25+tax) copy the article citation above and click Buy article